Intelligent Bio Solutions Inc. (NASDAQ: INBS), a leader in non-invasive medical testing technologies, is set to present groundbreaking pharmacokinetic (PK) study data at the upcoming ADLM 2025 Clinical Lab Expo in Chicago. The study underscores the efficacy of the company's Intelligent Fingerprinting Drug Screening System, demonstrating that fingerprint sweat can accurately reflect codeine levels comparable to those found in blood and saliva. This advancement positions the system as a viable, non-invasive alternative for drug screening in various settings.
The presentation, led by Daniel Brown, Head of Clinical Affairs at INBS, will take place during the Poster Hall sessions of the expo. The Intelligent Fingerprinting Drug Screening System, which has already been adopted by over 450 accounts across 24 countries, offers a rapid, hygienic, and cost-effective solution for detecting recent drug use. Its ability to deliver results in under ten minutes makes it particularly valuable for employers in safety-critical industries, among other applications.
This development is significant as it represents a leap forward in drug screening technology, offering a less invasive and more dignified method for individuals undergoing testing. The potential for broader applications of fingerprint sweat analysis in medical diagnostics and beyond could revolutionize how drug screening and other tests are conducted in the future. For more details on the study and the technology, visit https://ibn.fm/suGlJ.
